Charles River Laboratories (CRL) Earnings Analysis
Charles River Laboratories (CRL) beat expectations in Q2 FY2026 on revenue of $1.0B versus the $977.2M estimate (-2.7% YoY) and EPS of $3.02. The next Charles River Laboratories (CRL) earnings date is Nov 4, 2026. Below is the full Charles River Laboratories earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Charles River Laboratories (CRL) Earnings Analysis — key stats
Next earnings date
Nov 4, 2026
Latest reported quarter
Q2 FY2026
Earnings verdict
Beat
EPS beat rate
8 of last 8 (quarters above estimate)
Avg next-day move
±9.1% (over the last 8 reports)
Post-earnings direction
Up 5 / Down 3 (of the last 8 reports)
Implied move (next report)
±8.7% (options-derived · into Nov 4, 2026)
Institutional ownership
118.2% (13F as of 2026-06-30)
Top 10 holders
52.7% (of shares outstanding)
Insider activity
5 buys / 7 sells (recent Form 4 filings)
Revenue
$1.0B (vs $977.2M est · +2.8% surprise · -2.7% YoY)
EPS
$3.02 (vs $2.74 est · +10.2% surprise · -102.8% YoY)
Share price
$346.37 (+2.0%)
Market cap
$16.7B
Charles River Laboratories (CRL) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$1.0B vs $977.2M est
$3.02 vs $2.74 est
+10.2%
+13.4%
Beat
Q2 FY2026
$995.8M vs $977.5M est
$2.06 vs $1.96 est
+5.1%
-2.3%
Mixed
Q1 FY2026
$994.2M vs $987.0M est
$2.39 vs $2.33 est
+2.6%
+3.6%
Mixed
Q4 FY2025
$1.0B vs $987.2M est
$2.43 vs $2.32 est
+4.7%
-3.9%
Mixed
Q3 FY2025
$1.0B vs $968.9M est
$3.12 vs $2.50 est
+24.8%
-10.6%
Beat
Q2 FY2025
$984.2M vs $958.8M est
$2.34 vs $2.06 est
+13.6%
+22.5%
Beat
Q1 FY2025
$1.0B vs $948.2M est
$2.66 vs $2.50 est
+6.4%
+5.1%
Beat
Q4 FY2024
$1.0B vs $976.0M est
$2.59 vs $2.42 est
+7.0%
+11.5%
Beat
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Fmr LLC
8.7%
4.2M
$961.5M
+22.7%
Blackrock, INC.
7.8%
3.8M
$861.5M
-1.6%
Vanguard Capital Management LLC
6.5%
3.1M
$714.2M
-1.7%
Invesco Ltd.
6.2%
3.0M
$676.9M
+24.5%
Harris Associates L P
4.6%
2.2M
$508.3M
+4.1%
Vanguard Portfolio Management LLC
4.6%
2.2M
$501.4M
-3.6%
Allspring Global Investments Holdings, LLC
3.9%
1.9M
$436.5M
-4.4%
State Street Corp
3.8%
1.9M
$422.8M
-0.5%
Dimensional Fund Advisors LP
3.4%
1.6M
$373.8M
-0.2%
Ariel Investments, LLC
3.1%
1.5M
$341.6M
+4.3%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
Parisotto Shannon M
officer: CEVP, Disc & Safety Assessment
2026-10-05
Buy
981
$204480
Parisotto Shannon M
officer: CEVP, Disc & Safety Assessment
2026-10-05
Sell
981
$302580
Parisotto Shannon M
officer: CEVP, Disc & Safety Assessment
2026-10-05
Sell
981
$204480
Coleman Glenn
officer: EVP & Chief Financial Officer
2026-09-30
Buy
10
$2974
FOSTER JAMES C
director
2026-08-25
Buy
12K
$2.6M
FOSTER JAMES C
director
2026-08-25
Buy
21K
$4.1M
FOSTER JAMES C
director
2026-08-25
Sell
34K
$10.1M
FOSTER JAMES C
director
2026-08-25
Sell
12K
$2.6M
What you'll find
Next Charles River Laboratories (CRL) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Charles River Laboratories reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Charles River Laboratories (CRL)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Charles River Laboratories's next earnings date?
Charles River Laboratories's (CRL) next scheduled earnings date is Nov 4, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Charles River Laboratories (CRL) beat or miss earnings?
In Q2 FY2026, Charles River Laboratories (CRL) posted beat results — revenue of $1.0B versus the $977.2M estimate (+2.8% surprise) and EPS of $3.02 versus $2.74 expected (+10.2% surprise). Magnisto decodes every Charles River Laboratories (CRL) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Charles River Laboratories beat earnings estimates?
Over its last 8 reported quarters, Charles River Laboratories (CRL) beat Wall Street EPS estimates 8 times, most recently a beat result in Q3 FY2026. Magnisto tracks every Charles River Laboratories (CRL) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Charles River Laboratories stock move after earnings?
Over its last 8 quarterly reports, Charles River Laboratories (CRL) moved an average of ±9.1% the day after earnings — ranging from -10.6% (Q3 FY2025) to +22.5% (Q2 FY2025). The stock rose after 5 of those 8 reports and fell after 3. Heading into its next report on Nov 4, 2026, options-implied volatility is pricing in a move of roughly ±8.7% (derived). Magnisto tracks the realized post-earnings move for every Charles River Laboratories (CRL) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Charles River Laboratories?
Institutions hold about 118.2% of Charles River Laboratories's (CRL) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Fmr LLC (8.7%), Blackrock, INC. (7.8%), Vanguard Capital Management LLC (6.5%). Magnisto lists Charles River Laboratories's (CRL) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Charles River Laboratories (CRL)?
In the most recent Form 4 filings Magnisto tracks, Charles River Laboratories (CRL) insiders recorded 5 purchases and 7 sales — net selling. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Charles River Laboratories (CRL) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Charles River Laboratories (CRL), anchored to the current $346.37 share price, so you can weigh the bull, base and bear cases for Charles River Laboratories side by side.
Is Charles River Laboratories (CRL) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Charles River Laboratories fits your own thesis and risk profile. This is research, not investment advice.